Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00168792 · ClinicalTrials.gov registry record · Phase 4

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

A Phase 4 study, sponsored by Boehringer Ingelheim.

Terminated
Registry status
Phase 4
Development phase
1,671
Enrollment target

NCT00168792: Clinical Trial Phase 4 study, sponsored by Boehringer Ingelheim.

NCT00168792 is a Phase 4 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 1,671 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (223% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00168792, a Phase 4 study, was terminated before completion, sponsored by Boehringer Ingelheim.

TERMINATED
Registry status
Phase 4
Development phase
1,671 participants
Enrollment target

Study Summary

To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

Interventions

  • DRUG Tenecteplase
  • PROCEDURE PCI

Trial Details

FieldValue
Enrollment Target 1,671 participants
Start Date 2003-11
Phase Phase 4
Boehringer Ingelheim

515 total trials

Why NCT00168792 stopped before completion

NCT00168792 is an interventional study that assigns participants to a tested intervention. Its 1,671 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (223% higher).

The record links to 0 conditions, and to 2 interventions - of which Tenecteplase is the first listed.

NCT00168792 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00168792 about?

NCT00168792 is a clinical study titled "A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)". To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

What is the current status of trial NCT00168792?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1,671 participants. The study started on 2003-11.

What interventions are being tested in trial NCT00168792?

The interventions under investigation include: Tenecteplase (DRUG), PCI (PROCEDURE).

Who is sponsoring clinical trial NCT00168792?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00168792's enrollment target sits among peer trials

1,671 47th of 2000 higher than 1,954 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04852887 · 1,670 participants · Phase 3

    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • NCT06644625 · 1,665 participants

    CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

  • NCT06034405 · 1,663 participants

    Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

  • NCT06376565 · 1,680 participants · NA

    Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00168792, the US trial registry maintained by the National Library of Medicine. NCT00168792 (large enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.